InflaRx’s Izicopan Shows Rapid HS Results, 30% Cost Cuts Challenge Amgen’s Avacopan
InflaRx reported Phase 2a izicopan proof-of-concept data showing reductions in draining tunnels and pain within four weeks, with peak receptor inhibition and steady state reached in days versus Avacopan’s three-month timeline. The company cut fixed costs by 30% after halting its vilobelimab program and plans a regulator-engaged Phase 2b in spring.
1. Izicopan Phase 2a HS Results
InflaRx reported that its oral C5aR1 antagonist izicopan achieved reductions in draining tunnels and pain within four weeks in a Phase 2a hidradenitis suppurativa basket trial, reaching peak receptor inhibition and steady state within days in approximately 200 treated patients without hepatotoxicity signals.
2. Comparison to Avacopan
Management highlighted izicopan’s higher bioavailability, faster onset to steady state, much lower CYP3A4 inhibition and absence of hepatotoxicity signals versus Amgen’s Avacopan, positioning izicopan as a differentiated C5aR antagonist based on Phase 2a proof-of-concept data.
3. Cost Cuts and Phase 2b Plans
After deprioritizing its vilobelimab antibody program and halting its Phase 3 trial, InflaRx reduced its fixed cost base by roughly 30% and intends to host a Capital Markets Day in spring to finalize Phase 2b trial design, dose selection and regulatory engagement.